HC Wainwright Estimates Genelux’s Q1 Earnings (NASDAQ:GNLX)

Genelux Corporation (NASDAQ:GNLX) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Genelux in a note issued to investors on Thursday, November 6th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.26) for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.35) EPS.

Genelux (NASDAQ:GNLX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02.

Other analysts also recently issued research reports about the company. Maxim Group set a $20.00 target price on Genelux in a research note on Tuesday, October 21st. Lake Street Capital started coverage on shares of Genelux in a report on Tuesday, October 21st. They set a “buy” rating and a $16.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Genelux from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. Finally, Loop Capital set a $16.00 price target on shares of Genelux in a report on Tuesday, October 21st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Genelux Stock Performance

Shares of Genelux stock traded up $0.18 during trading hours on Friday, hitting $5.48. The company’s stock had a trading volume of 102,673 shares, compared to its average volume of 188,805. The company has a market cap of $206.79 million, a PE ratio of -6.22 and a beta of -0.09. The business has a 50 day moving average price of $5.13 and a two-hundred day moving average price of $3.75. Genelux has a 12-month low of $1.99 and a 12-month high of $8.53.

Hedge Funds Weigh In On Genelux

Several large investors have recently modified their holdings of the stock. Woodward Diversified Capital LLC grew its stake in Genelux by 15.2% in the first quarter. Woodward Diversified Capital LLC now owns 1,461,113 shares of the company’s stock worth $3,945,000 after purchasing an additional 192,808 shares in the last quarter. Liberty Wealth Management LLC purchased a new stake in shares of Genelux in the 1st quarter worth $45,000. Charles Schwab Investment Management Inc. bought a new position in shares of Genelux during the 1st quarter worth $68,000. American Century Companies Inc. purchased a new position in shares of Genelux during the first quarter valued at $51,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Genelux in the first quarter valued at about $215,000. Institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.